Methodology

All entries for: Novartis Pharmaceuticals Corporation

February 4, 2026

Novartis Pharmaceuticals Corporation

Orphan Drug Designation

treatment of progressive supranuclear palsy

Disease Area: Rare Disease
Source
Source
December 19, 2025

Novartis Pharmaceuticals Corporation

Orphan Drug Designation

FDA orphan drug designation: treatment of myasthenia gravis

Disease Area: Rare Diseases
Source
Source
Scroll to Top